A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
Open Access
- 27 April 2017
- journal article
- Published by Elsevier BV in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 1 (1), 111-116
- https://doi.org/10.1016/j.mayocpiqo.2017.04.003
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 18 references indexed in Scilit:
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung CancerJAMA Oncology, 2016
- Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase–Rearranged Anaplastic Thyroid CarcinomaJournal of Clinical Oncology, 2015
- ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic featuresLung Cancer, 2014
- Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancerProceedings of the National Academy of Sciences of the United States of America, 2014
- Identification of a Recurrent STRN/ALK Fusion in Thyroid CarcinomasPLOS ONE, 2014
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung CancerClinical Cancer Research, 2013
- Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencingThe Journal of Pathology, 2013
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion VariantsClinical Cancer Research, 2012
- EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFRJournal of Thoracic Oncology, 2012
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009